Christina Esdar

1.4k total citations
38 papers, 698 citations indexed

About

Christina Esdar is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Christina Esdar has authored 38 papers receiving a total of 698 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 17 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Christina Esdar's work include Ubiquitin and proteasome pathways (11 papers), Peptidase Inhibition and Analysis (7 papers) and Multiple Myeloma Research and Treatments (6 papers). Christina Esdar is often cited by papers focused on Ubiquitin and proteasome pathways (11 papers), Peptidase Inhibition and Analysis (7 papers) and Multiple Myeloma Research and Treatments (6 papers). Christina Esdar collaborates with scholars based in Germany, United States and United Kingdom. Christina Esdar's co-authors include Thomas Herget, Alfred Maelicke, Felix Rohdich, Djordje Müsil, Michael Busch, Michael Heinrich, Richard Schneider, Gerhild van Echten‐Deckert, Ulrich Grädler and Stefan Schütze and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Christina Esdar

38 papers receiving 683 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christina Esdar Germany	15	460	182	86	82	63	38	698
Christian Borgo Italy	18	702 1.5×	224 1.2×	56 0.7×	59 0.7×	99 1.6×	38	991
Joachim Bischof Germany	15	587 1.3×	210 1.2×	73 0.8×	51 0.6×	128 2.0×	33	826
Cesear Corona United States	15	627 1.4×	296 1.6×	149 1.7×	72 0.9×	58 0.9×	22	969
Vishal Pendharkar Singapore	12	714 1.6×	270 1.5×	137 1.6×	49 0.6×	68 1.1×	15	1.0k
Kevin R. Kupcho United States	10	481 1.0×	104 0.6×	80 0.9×	50 0.6×	48 0.8×	22	707
Theonie Anastassiadis United States	5	602 1.3×	181 1.0×	82 1.0×	65 0.8×	83 1.3×	6	817
Philip Ryan United States	14	514 1.1×	159 0.9×	83 1.0×	195 2.4×	53 0.8×	23	824
Frederick S. Vizeacoumar Canada	17	603 1.3×	226 1.2×	66 0.8×	122 1.5×	92 1.5×	51	912
Nanni Huser United States	8	737 1.6×	238 1.3×	79 0.9×	48 0.6×	75 1.2×	15	999
John M. Hatcher United States	16	574 1.2×	211 1.2×	252 2.9×	87 1.1×	65 1.0×	33	967

Countries citing papers authored by Christina Esdar

Since Specialization

Citations

This map shows the geographic impact of Christina Esdar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christina Esdar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christina Esdar more than expected).

Fields of papers citing papers by Christina Esdar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christina Esdar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christina Esdar. The network helps show where Christina Esdar may publish in the future.

Co-authorship network of co-authors of Christina Esdar

This figure shows the co-authorship network connecting the top 25 collaborators of Christina Esdar. A scholar is included among the top collaborators of Christina Esdar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christina Esdar. Christina Esdar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Esdar, Christina, Nina Linde, Andreas Blum, et al.. (2025). M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer. Molecular Cancer Therapeutics. 24(7). 1040–1053. 1 indexed citations

O’Leary, Ben, Heath D. Skinner, Jonathan D. Schoenfeld, et al.. (2024). Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck. Cancer Treatment Reviews. 129. 102773–102773. 7 indexed citations

Woźniak, Agnieszka, Ulla Vanleeuw, Nina Linde, et al.. (2023). Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST). Clinical Cancer Research. 29(15). 2859–2868. 9 indexed citations

Jiang, Feng, Jin Qi, Huakui Yu, et al.. (2023). Effect of extended treatment with IAP inhibitor xevinapant post radiotherapy (RT) on efficacy and the tumor microenvironment (TME) in preclinical models.. Journal of Clinical Oncology. 41(16_suppl). 6027–6027. 2 indexed citations

Schmelas, Carolin, et al.. (2023). Overcoming MET-mediated resistance in oncogene-driven NSCLC. iScience. 26(7). 107006–107006. 6 indexed citations

Ferris, Robert L., Kevin J. Harrington, Jonathan D. Schoenfeld, et al.. (2022). Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck. Cancer Treatment Reviews. 113. 102492–102492. 10 indexed citations

Woźniak, Agnieszka, Ulla Vanleeuw, Nina Linde, et al.. (2022). Abstract 2666: Anti-tumor effects of the novel KIT mutant inhibitor M4205 in patient-derived gastrointestinal stromal tumor (GIST) xenograft models. Cancer Research. 82(12_Supplement). 2666–2666. 2 indexed citations

Esdar, Christina, Manja Friese‐Hamim, Sofia Stinchi, et al.. (2022). Translational PK/PD Modeling of Tumor Growth Inhibition and Target Inhibition to Support Dose Range Selection of the LMP7 Inhibitor M3258 in Relapsed/Refractory Multiple Myeloma. Journal of Pharmacology and Experimental Therapeutics. 384(1). 163–172. 5 indexed citations

Sanderson, Michael P., Manja Friese‐Hamim, Michael Busch, et al.. (2021). M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models. Molecular Cancer Therapeutics. 20(8). 1378–1387. 30 indexed citations

10.

Bogatyrova, Olga, Johanna Sofia Margareta Mattsson, Edith Ross, et al.. (2021). FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response. European Journal of Cancer. 151. 136–149. 32 indexed citations

11.

Klein, Markus, Michael Busch, Manja Friese‐Hamim, et al.. (2021). Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i). Journal of Medicinal Chemistry. 64(14). 10230–10245. 27 indexed citations

12.

Yu, Ping, et al.. (2020). A novel monovalent FGFR1 antagonist: Preclinical safety profiles in rodents and non-human primates. Toxicology and Applied Pharmacology. 406. 115215–115215. 3 indexed citations

13.

Sanderson, Michael J., Michael P. Busch, Christina Esdar, et al.. (2019). Abstract DDT02-01: First-time disclosure of M3258: A selective inhibitor of the immunoproteasome subunit LMP7 with potential for improved therapeutic utility in multiple myeloma compared to pan-proteasome inhibitors. DDT02–1. 2 indexed citations

14.

Buchstaller, Hans‐Peter, Dieter Dorsch, Daniel Kühn, et al.. (2019). Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity. Journal of Medicinal Chemistry. 62(17). 7897–7909. 28 indexed citations

15.

Czodrowski, Paul, Aurélie Mallinger, Dirk Wienke, et al.. (2016). Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening. Journal of Medicinal Chemistry. 59(20). 9337–9349. 89 indexed citations

16.

Merkul, Eugen, Thomas J. J. Müller, Christina Esdar, et al.. (2016). Discovery of novel 7-azaindoles as PDK1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 26(13). 3073–3080. 16 indexed citations

17.

Grädler, Ulrich, Jörg Bomke, Djordje Müsil, et al.. (2013). Fragment-based discovery of focal adhesion kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(19). 5401–5409. 26 indexed citations

18.

Esdar, Christina, Sandra Milasta, Alfred Maelicke, & Thomas Herget. (2001). Differentiation-associated apoptosis of neural stem cells is effected by Bcl-2 overexpression: impact on cell lineage determination. European Journal of Cell Biology. 80(8). 539–553. 19 indexed citations

19.

Esdar, Christina, et al.. (1999). The protein kinase C (PKC) substrate GAP‐43 is already expressed in neural precursor cells, colocalizes with PKCη and binds calmodulin. European Journal of Neuroscience. 11(2). 503–516. 27 indexed citations

20.

Herget, Thomas, et al.. (1998). Retinoic Acid Induces Apoptosis‐Associated Neural Differentiation of a Murine Teratocarcinoma Cell Line. Journal of Neurochemistry. 70(1). 47–58. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact